FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MUELLER PETER						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]								eck all ap Dire	ctor er (give title	ng Pers	10% Ov Other (s below)	vner	
(Last) (First) (Middle)  C/O VERTEX PHARMACEUTICALS INCORPORATED  130 WAVERLY ST						3. Date of Earliest Transaction (Month/Day/Year) 08/29/2011									EVP, Globa	al R&	,		
150 WAVERLY 51						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02139					_									X Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City)	(S	tate)	(Zip)																
		Tab	le I - N	lon-Deri	vative	Sec	uriti	ies Ad	quire	d, D	isposed c	of, or Bo	eneficia	ly Own	ed				
Date				2. Transac Date (Month/Da		ear) Execut			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			Secu Bene Own	ficially ed Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Repo Trans (Insti	rted action(s) . 3 and 4)			(Instr. 4)	
Common Stock 08/29/20					2011	11			М		4,300	A	\$10.41	. 1	38,035		D		
Common Stock 08/29/20					2011	011					5,200	A	\$11.27	' 1	43,235		D		
Common Stock 08/29/20					2011	011			S <sup>(1)</sup>		9,500	D	\$45.01(2	)(3)	133,735		D		
Common Stock															4,495		I	401(k)	
		Т	able I								posed of converti			Owne	t				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)		ransaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exerc tion Da l/Day/\		7. Title at Amount Securitie Underlyit Derivativ (Instr. 3 a	of s ng e Security	8. Price of Derivative Security (Instr. 5)		e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares						
Stock Options	\$10.41	08/29/2011			M			4,300	(4)	)	02/02/2015	Common Stock	4,300	\$0.00	0		D		
Stock Ontions	\$11.27	08/29/2011			M			5,200	(4)	)	10/06/2014	Common	5,200	\$0.00	12,80	0	D		

## **Explanation of Responses:**

- 1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$45.01 (range \$45.00 to \$45.26).
- 3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Fully vested.

## Remarks:

Kenneth S. Boger, Attorney-In-08/30/2011

**Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.